Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B1S5 is a specific combination of 0.1% bupivacaine and 5 µg sufentanil, formulated in 15 mL, used for epidural analgesia during labor. Bupivacaine is a local anesthetic that blocks nerve impulses by decreasing the permeability of neuronal membranes to sodium ions, thereby inhibiting depolarization. Sufentanil is a potent synthetic opioid analgesic that acts as an agonist at mu-opioid receptors in the central nervous system, leading to pain relief and sedation. This combination aims to provide effective analgesia with minimal side effects during labor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + sufentanil (0.1% bupivacaine + 5 µg sufentanil).